Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections: A Secondary Analysis of the - Report - MDSpire

Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections: A Secondary Analysis of the

  • By

  • Rayoun Ramendra

  • Julie K. Wright

  • Kevin C. Kain

  • Bridget Kim

  • Hridesh Mishra

  • Kathleen Zhong

  • Pierre Aslanian

  • Alex Carignan

  • John Conly

  • Michael Detsky

  • Erick Duan

  • Gerald Evans

  • Jan O. Friedrich

  • Francois Lamontagne

  • Francois Lauzier

  • Derek R. Macfadden

  • John Marshall

  • Lauralyn McIntyre

  • John Muscedere

  • Andrew Morris

  • Ruxandra Pinto

  • Asgar Rishu

  • Henry T. Stelfox

  • Linda R. Taggart

  • Jennifer Tsang

  • Alexis F. Turgeon

  • Rob Fowler

  • Nick Daneman

  • June 29, 2026

  • 0 min

Share

Clinical Report: Utilizing Procalcitonin Levels to Determine Optimal Duration of Antibiotic Treatment for Bloodstream Infections

Background

Bloodstream infections are a significant cause of morbidity and mortality, necessitating timely antibiotic therapy. The BALANCE trial established that a 7-day antibiotic course is noninferior to a 14-day course regarding 90-day mortality for most BSIs, prompting further investigation into biomarkers like procalcitonin to personalize treatment duration.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • Procalcitonin (PCT) is a biomarker that can indicate the severity of bacterial infections.
  • The BALANCE trial demonstrated noninferiority of a 7-day antibiotic course compared to 14 days regarding 90-day mortality.
  • In the BALANCE-PCT analysis, serum PCT levels were measured after 7 days of antibiotic treatment.
  • High PCT levels on day 7 may correlate with differential mortality outcomes in patients receiving different durations of antibiotic therapy.
  • Compliance with PCT-based recommendations in clinical practice has been noted to be modest.

Clinical Implications

Understanding the relationship between PCT levels and patient outcomes could enhance personalized treatment approaches.

Conclusion

The findings from this secondary analysis of the BALANCE trial contribute to the understanding of procalcitonin in relation to antibiotic treatment duration in bloodstream infections.

Related Resources & Content

  1. Critical Care (Springer), 2025 -- Cost-effectiveness of procalcitonin-guided antibiotic duration for hospitalized patients with sepsis
  2. Frontiers in Medicine -- Compliance of procalcitonin-guided antibiotic therapy in adult infectious patients in China: a multicenter real-world retrospective study
  3. JAMA Network Open -- Procalcitonin—An Enigmatic Anxiolytic Biomarker
  4. Intensive Care Medicine -- Utilizing Procalcitonin to Direct Initial Antibiotic Treatment in ICU Patients with Acute COPD Exacerbations: Results from a Randomized Multicenter Trial
  5. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 - PMC
  6. Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial - PMC
  7. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine
  8. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 - PMC
  9. Biomarker-Guided Antibiotic Duration for Hospitalized Patients With Suspected Sepsis: The ADAPT-Sepsis Randomized Clinical Trial - PMC
  10. Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections | New England Journal of Medicine

Original Source(s)

Procalcitonin to Guide 7 vs 14 Days of Antibiotics in Bloodstream Infections: A Secondary Analysis of the

  • by Rayoun Ramendra, Julie K. Wright, Kevin C. Kain, Bridget Kim, Hridesh Mishra, Kathleen Zhong, Pierre Aslanian, Alex Carignan, John Conly, Michael Detsky, Erick Duan, Gerald Evans, Jan O. Friedrich, Francois Lamontagne, Francois Lauzier, Derek R. Macfadden, John Marshall, Lauralyn McIntyre, John Muscedere, Andrew Morris, Ruxandra Pinto, Asgar Rishu, Henry T. Stelfox, Linda R. Taggart, Jennifer Tsang, Alexis F. Turgeon, Rob Fowler, Nick Daneman

  • June 29, 2026

Related Content

When Bad Data Enters the Drug Pipeline

Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

Procalcitonin—An Enigmatic Anxiolytic Biomarker

Assessment of differences in immune responses to albumin compared with crystalloids for resuscitation in sepsis